Negotiations are not the only way 3 PD-1 models enter Foshan's commercial supplementary medical insurance

On December 23, Foshan Medical Insurance Bureau issued the announcement of "Foshan social insurance fund administration on the implementation of Foshan commercial supplementary medical insurance" Ping An Buddhist medical insurance " Foshan commercial supplementary medical insurance "Ping An Buddhist medical insurance" will be implemented from January 1, 2020 "Ping'an Foshan medical insurance" insurance product is underwritten and operated by Foshan Central Branch of Ping'an Endowment Insurance Co., Ltd (hereinafter referred to as "Ping'an endowment Foshan branch"), with the premium standard of 185 yuan / person / year in 2020 and the guarantee period from January 1, 2020 to December 31, 2020 In the insured year, 80% of the medical expenses of more than 20000 yuan (including) are reimbursed for the inpatient (including family bed) and outpatient chronic diseases within the scope of the medical insurance catalogue, and the maximum annual reimbursement limit is 1 million yuan It is worth mentioning that in the detailed rules of liability, the compensation for self paid drugs for malignant tumors is mentioned The insured will be reimbursed 90% for the treatment of specific tumor diseases in the outpatient department of basic medical insurance During the year of insurance, the total amount of self paid therapeutic drugs used is more than 10000 yuan, and the part within 150000 yuan (included) The cost-effective drugs for cancer treatment include chemotherapy drugs, targeted drugs, immune agents, etc The catalogue lists 15 cancer drugs that participate in the commercial supplementary medical insurance, including three PD-1 drugs: nafulizumab injection, pabolizumab injection and treprizumab injection In fact, Foshan is not the first case On November 21, 2018, Shenzhen human resources and Social Security Bureau announced the list of drugs to be applied for supplementary medical insurance for serious and serious diseases in 2018, including several heavy-duty anticancer drugs listed in 2018 In March 2019, Shenzhen city added 6 varieties of aleatinib hydrochloride capsule (ansanza), pabolizumab injection (coreda), olapari tablet (Lipitor), lucotinib phosphate tablet (jiekewei), piperacillin capsule (iboxin) and lanruitide acetate for injection (somadoulin) Before, some people wondered whether the failure of health care negotiations would have a bad impact on enterprises? In fact, entering the medical insurance is not the only way Innovative drugs have their own unique clinical value They have not entered the medical insurance through negotiation, and there are many channels to expand the market Within the available range, enterprises need to comprehensively consider and get a variety of solutions Commercial medical insurance is one of them.